{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:14:35Z","timestamp":1788902075550,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114236","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T07:03:40Z","timestamp":1721718220000},"page":"114236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1\/randomised phase 2 SCALOP-2 trial"],"prefix":"10.1016","volume":"209","author":[{"given":"Somnath","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Radhakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep S.","family":"Virdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Tranter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thankamma V.","family":"Ajithkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarshi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Scott-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sebag-Montefiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim S.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9791","key":"10.1016\/j.ejca.2024.114236_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2024.114236_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2024.114236_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174326","article-title":"Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-a systematic review and meta-analysis","volume":"13","author":"Damm","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","article-title":"Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer","volume":"68","author":"Murphy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ejca.2024.114236_bib7","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2024.114236_bib8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: american society of clinical oncology clinical practice guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2024.114236_bib9","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114236_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.ejca.2024.114236_bib11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/bjc.2017.95","article-title":"Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer","volume":"116","author":"Hurt","year":"2017","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.ejca.2024.114236_bib12","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.ejca.2024.114236_bib13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.clon.2018.02.067","article-title":"Stomach dose-volume predicts acute gastrointestinal toxicity in chemoradiotherapy for locally advanced pancreatic cancer","volume":"30","author":"Holyoake","year":"2018","journal-title":"Clin Oncol (R Coll Radio)"},{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib14","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.ijrobp.2012.09.035","article-title":"Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer","volume":"85","author":"Kelly","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"10.1016\/j.ejca.2024.114236_bib15","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","article-title":"HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo","volume":"65","author":"Gupta","year":"2005","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ejca.2024.114236_bib16","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-09-1324","article-title":"Radiosensitization of epidermal growth factor receptor\/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status","volume":"16","author":"Kimple","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.114236_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-018-0904-2","article-title":"Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells","volume":"37","author":"Veschi","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.114236_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","article-title":"ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radio Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.114236_bib20","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114236_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12885-019-5307-z","article-title":"Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine \u00b1 nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)","volume":"19","author":"Strauss","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2024.114236_bib22","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114236_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13014-022-02076-5","article-title":"Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review","volume":"17","author":"Vornh\u00fclz","year":"2022","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114236_bib25","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijrobp.2015.08.026","article-title":"Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer","volume":"93","author":"Hurt","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2024.114236_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1748-717X-7-156","article-title":"Radiation dose \u226554 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation","volume":"7","author":"Golden","year":"2012","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114236_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prro.2013.01.005","article-title":"Radiation dose responses for chemoradiation therapy of pancreatic cancer: an analysis of compiled clinical data using biophysical models","volume":"4","author":"Moraru","year":"2014","journal-title":"Pr Radiat Oncol"},{"key":"10.1016\/j.ejca.2024.114236_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.013","article-title":"Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)","volume":"17","author":"Suker","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.ejca.2024.114236_bib29","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114236_bib30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2024.114236_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0971-5916.180201","article-title":"Targeting the AKT pathway: repositioning HIV protease inhibitors as radiosensitizers","volume":"143","author":"Goda","year":"2016","journal-title":"Indian J Med Res"},{"issue":"18","key":"10.1016\/j.ejca.2024.114236_bib32","doi-asserted-by":"crossref","first-page":"9252","DOI":"10.1158\/0008-5472.CAN-06-1239","article-title":"Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy","volume":"66","author":"Pore","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2024.114236_bib33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2016.03.024","article-title":"The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells","volume":"119","author":"Al-Assar","year":"2016","journal-title":"Radio Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114236_bib34","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-18-2466","article-title":"Clinical development of novel drug-radiotherapy combinations","volume":"25","author":"Ahmad","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.114236_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114236_bib36","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Rainer Fietkau","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492400892X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492400892X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T16:47:08Z","timestamp":1729615628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492400892X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":36,"alternative-id":["S095980492400892X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114236","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1\/randomised phase 2 SCALOP-2 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114236"}}